Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Multivitamin and Iron Supplementation to Prevent Periconceptional Anemia in Rural Tanzanian Women: A Randomized, Controlled Trial

  • Nilupa S. Gunaratna ,

    Affiliation Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America

  • Honorati Masanja,

    Affiliation Ifakara Health Institute, Dar es Salaam, Tanzania

  • Sigilbert Mrema,

    Affiliation Ifakara Health Institute, Dar es Salaam, Tanzania

  • Francis Levira,

    Affiliation Ifakara Health Institute, Dar es Salaam, Tanzania

  • Donna Spiegelman,

    Affiliation Departments of Epidemiology, Biostatistics, and Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America

  • Ellen Hertzmark,

    Affiliation Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America

  • Naomi Saronga,

    Affiliation Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

  • Kahema Irema,

    Affiliation Ifakara Health Institute, Dar es Salaam, Tanzania

  • Mary Shuma,

    Affiliation Ifakara Health Institute, Dar es Salaam, Tanzania

  • Ester Elisaria,

    Affiliation Ifakara Health Institute, Dar es Salaam, Tanzania

  • Wafaie Fawzi

    Affiliation Departments of Global Health and Population, Epidemiology, and Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America

Multivitamin and Iron Supplementation to Prevent Periconceptional Anemia in Rural Tanzanian Women: A Randomized, Controlled Trial

  • Nilupa S. Gunaratna, 
  • Honorati Masanja, 
  • Sigilbert Mrema, 
  • Francis Levira, 
  • Donna Spiegelman, 
  • Ellen Hertzmark, 
  • Naomi Saronga, 
  • Kahema Irema, 
  • Mary Shuma, 
  • Ester Elisaria



Women’s nutritional status during conception and early pregnancy can influence maternal and infant outcomes. This study examined the efficacy of pre-pregnancy supplementation with iron and multivitamins to reduce the prevalence of anemia during the periconceptional period among rural Tanzanian women and adolescent girls.


A double-blind, randomized controlled trial was conducted in which participants were individually randomized to receive daily oral supplements of folic acid alone, folic acid and iron, or folic acid, iron, and vitamins A, B-complex, C, and E at approximately single recommended dietary allowance (RDA) doses for six months.


Rural Rufiji District, Tanzania.


Non-pregnant women and adolescent girls aged 15–29 years (n = 802).


The study arms were comparable in demographic and socioeconomic characteristics, food security, nutritional status, pregnancy history, and compliance with the regimen (p>0.05). In total, 561 participants (70%) completed the study and were included in the intention-to-treat analysis. Hemoglobin levels were not different across treatments (median: 11.1 g/dL, Q1-Q3: 10.0–12.4 g/dL, p = 0.65). However, compared with the folic acid arm (28%), there was a significant reduction in the risk of hypochromic microcytic anemia in the folic acid and iron arm (17%, RR: 0.61, 95% CI: 0.42–0.90, p = 0.01) and the folic acid, iron, and multivitamin arm (19%, RR: 0.66, 95% CI: 0.45–0.96, p = 0.03). Inverse probability of treatment weighting (IPTW) to adjust for potential selection bias due to loss to follow-up did not materially change these results. The effect of the regimens was not modified by frequency of household meat consumption, baseline underweight status, parity, breastfeeding status, or level of compliance (in all cases, p for interaction>0.2).


Daily oral supplementation with iron and folic acid among women and adolescents prior to pregnancy reduces risk of anemia. The potential benefits of supplementation on the risk of periconceptional anemia and adverse pregnancy outcomes warrant investigation in larger studies.

Trial Registration NCT01183572


Anemia during pregnancy has been associated with adverse outcomes including maternal and perinatal mortality, pre-term delivery, and low birth weight [1, 2]. While iron deficiency is considered the leading cause of anemia, other causes include deficiencies in micronutrients such as folate, vitamin B12, and vitamin A, infestations with parasites such as helminths or malaria, genetically-inherited hemoglobinopathies, HIV/AIDS, and chronic inflammation [3, 4]. Iron requirements increase over the course of pregnancy and, later in pregnancy, exceed amounts that could be absorbed even from an optimal diet [5]. Pregnant women must therefore enter pregnancy with sufficient iron stores to meet their full requirements. However, many women, especially in developing countries, enter pregnancy with iron as well as other nutrient deficiencies and consequently suffer from nutritional anemias due to food insecurity, suboptimal diets, increased morbidity, early initiation of childbearing, multiple pregnancies, short inter-pregnancy intervals, and prolonged lactation [6]. Nutrient availability is important around conception and during early pregnancy for key developmental processes including implantation, placental formation and function, embryogenesis, and fetal organogenesis [7]. For most women, these needs occur before they seek antenatal care. Nutrient supplementation of women of reproductive age may therefore be an effective strategy to improve nutritional status of at-risk women prior to and in preparation for pregnancy.

There is growing interest in the effect of maternal pre-pregnancy and periconceptional nutritional status on maternal and infant outcomes. The benefits of periconceptional folic acid supplementation for reducing the risk of neural tube defects has been well demonstrated through randomized, controlled studies [8] as well as evaluations of national fortification programs [9]. Preconceptional anemia among women of reproductive age in China was associated with fetal growth restriction and lower birth weight [10]. Preconceptional iron-deficiency anemia in particular had a strong negative association with birth weight, as did anemia related to deficiency of at least one of folate, vitamin B6, or vitamin B12. An intervention to provide weekly iron and folic acid supplements to women of reproductive age in Vietnam reduced anemia, iron deficiency, and iron-deficiency anemia in non-pregnant women with benefits that continued through the first and second trimesters of pregnancy; however, in the third trimester, the rates of these endpoints were comparable with those of women receiving daily iron-folic acid supplements with no preconceptional supplementation [11]. Using a shared protocol and similar target populations [12], a second study in the Philippines found that weekly iron-folic acid supplementation improved serum ferritin and hematocrit but not hemoglobin [13], while a third study in Cambodia found improved hemoglobin levels with increasing effectiveness among women of higher socioeconomic status [14]. Randomized studies on the efficacy of supplementation to improve periconceptional anemia, however, are lacking in Africa, where nutritional deficiencies are widespread, the burden of anemia is high among non-pregnant (48%) and pregnant (57%) women, and there is some evidence that these rates are increasing [15, 16].

In Tanzania, 40% of women of reproductive age are anemic, with significant variation among regions [17]. Eleven percent are underweight, with more undernutrition in rural than in urban areas. Among rural mothers, less than one in three consume iron-rich foods in a 24-hour period, and only 3% took iron supplements for 90 or more days during their last pregnancy. Meanwhile, 58% of girls initiate sexual activity by the age of 18 years, with the fertility rate at 5.4 children per woman and the median birth interval below three years [17]. While 98% of Tanzanian women seek antenatal care at some time during pregnancy, the median gestational age at the first antenatal visit is over five months [18]. We therefore conducted a randomized controlled trial of iron and multivitamin supplementation among non-pregnant women and adolescent girls in a rural district of Tanzania to determine the effect of supplementation on anemia during the periconceptional period.


Ethics statement

The study was approved by the Institutional Review Boards (IRBs) at the Harvard School of Public Health, Ifakara Health Institute, and National Institute for Medical Research (Tanzania) and registered in the United States Clinical Trials registry ( identifier NCT01183572). The Tanzania Food and Drug Authority approved the use of the regimens. All participants provided written informed consent themselves or through a legal guardian if under 18 years of age.

Study design and intervention

A double-blind, randomized controlled trial of non-pregnant women and adolescent girls was conducted in Ikwiriri and Kibiti, two rural wards in Rufiji District, Pwani Region, Tanzania. Participants were recruited between October 2010 and June 2011 and randomly assigned to receive daily oral supplements of folic acid alone, folic acid and iron, or folic acid, iron, and vitamins A, B-complex, C, and E. All supplements were provided for six months in approximately single recommended dietary allowance (RDA) doses (Table 1) [1921]. The three study supplements were manufactured by Tishcon Corporation (Salisbury, MD) and were indistinguishable in appearance and taste. The primary objective was to determine whether daily oral supplementation with folic acid and iron or with folic acid, iron, and multivitamins would reduce the risk of anemia when compared with supplementation with folic acid alone. Given its known benefits during the periconceptional period [8, 9], folic acid was provided as the comparison regimen rather than a placebo.

Table 1. Daily amounts of vitamins and iron provided by the study regimens.

Women were eligible for the study if they were between 15 and 29 years of age, not pregnant, planning to remain in the study area for six months, and willing to provide written informed consent themselves or through a guardian if under 18 years of age. Women were excluded if they had amenorrhea, had given birth within the past six months, were already taking vitamin supplements, or had any severe illness requiring hospitalization during screening or enrollment. In total, 802 women and adolescent girls were enrolled. While the initial target sample size was 1800 participants, as this study was intended as a pilot to assess the feasibility of micronutrient supplementation in a rural population during the periconceptional period, the final sample size was based on the timeline and resources available, and this change was reported to the IRBs. Of the enrolled participants, 561 or a minimum of 183 per treatment arm completed the laboratory evaluation following six months of supplementation. In a pairwise comparison of a treatment arm to the arm providing folic acid alone, the study had 80% power at a 5% significance level to detect a 0.5 g/dL change in hemoglobin level using an independent samples t-test or a 29% reduction (absolute reduction of 14%) in the risk of anemia using a χ2 test of independence, assuming a standard deviation of 1.8 g/dL for hemoglobin and 50% prevalence of anemia in the folic acid arm.

Recruitment and randomization

Potential participants were first screened for eligibility through an existing demographic surveillance system (DSS) in the two wards. Women were interviewed at their homes during a regularly scheduled DSS visit and those meeting the eligibility criteria were referred to their ward health clinic where their eligibility was confirmed, they received information about the study, and informed consent was obtained. All women who travelled to their ward health clinic were reimbursed for round-trip travel expenses regardless of whether they enrolled in the study. During household screening, women were initially considered not pregnant if they had had a menstrual period in the preceding four weeks; however, given that some women had delayed menstrual periods due to naturally longer cycles, lactation, or contraceptive use or had poor recall of their menstrual history, this criterion was revised for initial screening to having had a menstrual period in the preceding six weeks. During eligibility confirmation at ward clinics, women determined not to have had a menstrual period in the preceding four weeks were then given a urine pregnancy test to confirm absence of pregnancy.

Eligible, consenting participants were individually randomized in equal numbers to one of the three interventions (Table 1) and given their first bottle of regimen with instructions for use. Allocation was performed according to a computer-generated randomization sequence using blocks of size 15 created by a scientist not involved in data collection or analysis. At enrollment, research staff assigned each eligible person to the next numbered bottle at that site. At each subsequent visit, study supplements were dispensed in identical bottles labeled with the participant’s study identification number and prepared by pharmacists who had no contact with the participants. All participants and research staff were blinded to the intervention allocation. During randomization, data were also collected on participants’ demographic and socioeconomic characteristics, diet using a food frequency questionnaire, height, weight, and middle upper arm circumference (MUAC).


Following randomization, study supplements were dispensed during monthly home visits, during which data were collected on compliance with the regimen, reasons for non-compliance, any reported symptoms since the last study visit, and menstrual history. Compliance was assessed through participants’ self-reporting and pill counts. The final study visit was conducted at the local ward clinic, where participants’ height, weight, and MUAC were measured and peripheral venous blood was collected by trained laboratory technicians using EDTA vacutainer tubes and transported to Mchukwi Mission Hospital in Mchukwi, Pwani Region, for determination of complete blood cell counts using a Sysmex KX-21N Automated Hematology Analyzer. Peripheral venous blood was also used to prepare a thin blood smear to type anemia and a thick blood smear that was read by two independent laboratory technicians to assess malaria parasitemia. A third reading was conducted as needed to resolve discrepant readings. Though originally planned, these laboratory assessments could not be obtained on the study participants at baseline. Information was obtained from relatives or neighbors if a participant was not available for a scheduled visit at home or at the clinic, and all efforts were made to reach participants who traveled within the study area for family reasons or for work including seasonal farm labor.

Outcome measures

Hemoglobin concentration (Hb), mean corpuscular volume (MCV), red cell distribution width (RDW, measured as the coefficient of variation or CV of the MCV x 100 [22]), and mean corpuscular hemoglobin (MCH) were measured by complete blood cell count. Anemia was defined as Hb<11 g/dL, severe anemia as Hb<8.5 g/dL, microcytosis as MCV<80 fL, and hypochromia as MCH<27 pg [22, 23]. Hypochromic microcytic anemia was defined as Hb<11 g/dL, MCV<80 fL, and MCH<27 pg. Normocytic anemia was identified as Hb<11 g/dL and 80≤MCV≤100 fL. Malaria infection was identified by presence of Plasmodium parasites observed by light microscopy in a thick peripheral blood smear. Compliance with the regimen was calculated as the number of tablets taken from all returned regimen bottles divided by the total number of days the participant used those bottles.

Statistical analysis

Analyses were based on the intention-to-treat principle and included all randomized participants. Distributions of quantitative outcomes were summarized using the median, the first quartile (Q1), and the third quartile (Q3) of the observed distributions. Differences in baseline measures among the treatment arms were assessed with χ2 tests of independence for categorical variables and Kruskal-Wallis tests for continuous variables. Pairwise comparisons of outcomes in each treatment arm versus the folic acid arm were made using χ2 tests of independence for categorical variables and Wilcoxon rank-sum tests for continuous variables. The relative risk (RR) of an outcome was calculated as the proportion of participants experiencing the outcome in a given treatment arm divided by the proportion of participants experiencing the outcome in the folic acid arm, and 95% confidence intervals (CI) for relative risks were calculated using a standard formula [24]. To adjust for any potential selection bias due to loss to follow-up, the main analysis of differences in outcomes between the two treatment arms and the folic acid arm was repeated using inverse probability of treatment weighting (IPTW) [25]. Weights were calculated as the inverse of predicted values from a logistic regression of the following categorical variables on loss to follow-up: infrequent (less than once per week) household meat consumption, underweight status (body mass index [BMI] < 18.5 kg/m2) at baseline, high parity (two or more previous pregnancies) at baseline, breastfeeding status at baseline, ever reporting side effects (e.g., nausea, vomiting) during the intervention, ever reporting a feeling of having more energy or strength during the intervention, ever reporting better ability to concentrate during the intervention, ever reporting better ability to work during the intervention, and low compliance (supplements taken on less than 80% of days during the intervention). These factors were chosen because they were plausible risk factors for anemia or possible consequences of supplementation. For all outcomes, effects of the folic acid and iron and the folic acid, iron, and multivitamin treatments compared with the folic acid treatment were estimated using weighted log-binomial models with empirical standard errors [26]. Modification of the regimen effect on hypochromic microcytic anemia by infrequent household meat consumption, underweight status at baseline, high parity at baseline, breastfeeding status at baseline, and low compliance was assessed using the Breslow-Day test [24]. All P-values were two-sided. SAS version 9.2 (SAS Institute Inc., Cary, NC) was used for all analyses.


Study population

Of the 2783 women screened for eligibility through the DSS, 1499 (54%) were referred to a clinic for eligibility confirmation and randomization (Fig 1). The primary reason for exclusion was the lack of a menstrual period during screening (n = 868). Relaxing the criterion from having had a menstrual period in the preceding four weeks to having had a menstrual period in the preceding six weeks allowed more women to be referred to their ward health clinics for further screening with the use of a urine pregnancy test if necessary. Use of nutritional supplements outside of pregnancy was very rare in this population, accounting for only 0.1% of exclusions through the DSS.

Of the women referred, 802 (54%) traveled to the clinics and were confirmed as eligible, consented, and randomized to one of the three study arms (Fig 1). Seventy percent (n = 561) completed the six-month intervention and underwent laboratory assessments at the endpoint, while 14% (n = 109) withdrew, the reasons for which included symptoms that may (e.g., nausea) or may not (e.g., skin rash) have been related to the intervention, pressure from relatives to discontinue, or new pregnancy. Eleven percent (n = 91) migrated out of the study area, reflecting the mobility of this population. Specific reasons for migration included a change in marital status (i.e., marriage or divorce), movement to live with relatives, or movement to a more urban area to seek a new livelihood. Five percent (n = 40) were lost to follow-up, some of whom moved temporarily for seasonal farming activities. One woman died from severe malaria prior to completion of the study. Recruitment and follow-up extended from October 2010 to December 2011, when all follow-up was completed.

The study arms were comparable with respect to demographic and socioeconomic characteristics, food security (as assessed by household per capita food expenditure and meat consumption), nutritional status (as assessed by BMI), and pregnancy history (p>0.05, Table 2). Study participants were young women aged 21 years on average. One in four was under 18 years. Thirty-seven percent were currently married, 57% had been previously pregnant, and 24% were breastfeeding at the time of randomization. Only a quarter of women had education beyond the primary level, and 18% had no formal education. The majority of participants were housewives, worked on the family farm, or were unemployed. Poverty was high in this population, with two-thirds of participants living in homes with mud floors and only 11% with access to electricity. Household food expenditures were low, and 42% of participants stated that they did not regularly purchase food, reflecting the high reliance on subsistence agriculture in this population. The majority of households consumed meat less than once per month. Seventeen percent of participants were underweight (BMI<18.5 kg/m2) and 14% were overweight (BMI≥25 and <30 kg/m2) or obese (BMI≥30 kg/m2). Compliance with the regimen did not differ by study arm, with a median compliance of 82% in the folic acid arm, compared with 84% in the folic acid and iron arm (p = 0.40) and 83% in the folic acid, iron, and multivitamin arm (p = 0.67).

Table 2. Basic characteristics of the study population at recruitment (n = 802).

Anemia and malaria

Hemoglobin levels were not different in the three arms following the six-month intervention, with median values of 10.9 g/dL (Q1-Q3: 9.9–12.4) in the folic acid arm, compared with 11.1 g/dL (Q1-Q3: 10.0–12.4, p = 0.64) in the folic acid and iron arm and 11.4 g/dL (Q1-Q3: 10.0–12.4, p = 0.36) in the folic acid, iron, and multivitamin arm. Nearly half of women were anemic and 5% were severely anemic despite six months of supplementation, with no significant differences among the study arms (Table 3). Compared with the folic acid regimen (42%), the folic acid and iron regimen significantly reduced the risk of microcytosis (30%, RR: 0.72, 95% CI: 0.54–0.94, p = 0.02), and the folic acid, iron, and multivitamin regimen had a similar effect, though the result was not statistically significant (34%, RR: 0.81, 95% CI: 0.62–1.05, p = 0.12). Compared with the folic acid regimen (28%), the folic acid and iron regimen (17%, RR: 0.61, 95% CI: 0.42–0.90, p = 0.01) and the folic acid, iron, and multivitamin regimen (19%, RR: 0.66, 95% CI: 0.45–0.96, p = 0.03) significantly reduced the risk of hypochromic microcytic anemia. Pooling the iron-containing arms, iron supplementation with or without micronutrients reduced the risk of hypochromic microcytic anemia by 37% (95% CI: 13–54%, p = 0.005). Red cell distribution width was marginally reduced in the folic acid and iron (median CV: 13.5, Q1-Q3: 12.8–14.3, p = 0.08) and in the folic acid, iron, and multivitamin (median CV: 13.4, Q1-Q3: 12.6–14.3, p = 0.09) arms, compared with the folic acid arm (median CV: 13.7, Q1-Q3: 12.8–14.8). The study arms did not differ in risk of normocytic anemia or malaria infection following the intervention. IPTW to adjust for potential selection bias due to loss to follow-up did not materially change these results. The effect of the regimens on hypochromic microcytic anemia was not modified by infrequent household meat consumption; baseline underweight status, high parity, or breastfeeding status; or level of compliance (p>0.2).

Table 3. Effect of six months of supplementation with iron and multivitamins on risk of anemia and malaria.


Growing evidence on the importance of maternal nutritional status during conception and early pregnancy suggests that interventions to improve periconceptional nutritional status could reduce the risk of adverse maternal and perinatal outcomes. To the authors’ best knowledge, this is the first community-based randomized, controlled trial to provide nutrient supplementation to improve periconceptional anemia status in Sub-Saharan Africa. We found that daily oral supplementation with iron and folic acid prior to conception reduced the risk of hypochromic microcytic anemia by 37% in women and adolescent girls when compared with supplementation with folic acid alone. Iron deficiency is the primary cause of hypochromic microcytic anemia [27], and the high prevalence of this form of anemia and the population’s responsiveness to iron supplementation suggest that iron deficiency is a significant problem and supplementation would be beneficial.

Iron plays important roles during conception, placental formation, and early fetal development [7], and deficiency during this period can affect perinatal and infant outcomes directly through its influence on these processes [6, 2830] or indirectly through effects on anemia and iron status later in pregnancy [10, 31, 32] or postpartum [33]. In Tanzania, iron and folic acid are provided during pregnancy through the health system; however, women often delay initiation of antenatal care [17, 18] and use of these supplements can be low [34]. The key periods of periconception and early pregnancy are therefore missed and the duration of subsequent supplementation may be insufficient to correct nutritional deficiencies or alleviate anemia. Pre-pregnancy iron and folic acid supplementation may therefore be efficacious in improving periconceptional anemia status and consequently maternal and infant outcomes. In this study, inclusion of multivitamins did not reduce the risk of anemia beyond the reduction from supplementation with iron and folic acid alone. However, statistical power may have been limited in this pilot study, and the potential effect of multivitamin supplementation on the risks of periconceptional anemia and adverse perinatal outcomes warrants further investigation in larger studies, particularly in Sub-Saharan Africa, where many women enter pregnancy with multiple nutrient deficiencies.

The trending but statistically non-significant findings for hemoglobin and anemia may have resulted from the effect of supplementation on cases of microcytic anemia being obscured by the lack of effect on normocytic cases. A larger study with more statistical power may detect overall effects on hemoglobin and anemia, as has been observed in other iron and folic acid supplementation studies [35, 36]. Further, folic acid supplementation alone may reduce anemia [32], reducing the observed differences between the treatment arms and the folic acid arm following supplementation. The lack of baseline data does not allow examination of whether hemoglobin levels increased or the risk of anemia decreased in the folic acid arm after supplementation. The lack of a baseline also prevents correction for baseline status in analyses of treatment effects; however, due to randomization, systematic differences in baseline status among the study arms are unlikely and the lack of correction for baseline status is consequently not expected to influence the results. Comparison of participant characteristics at baseline further found no differences among the study arms.

The use of hypochromic microcytic anemia as an indirect marker of iron deficiency anemia has limitations, given that hypochromic microcytic anemia has other causes such as hemoglobinopathies, in particular thalassemias. In Tanzania, α0 and β thalassemias are rare, while the prevalence of α+ thalassemia heterozygosity is approximately 2% [37]. While they can influence study outcomes, these genetic disorders are expected to be equally prevalent in each study arm due to randomization; therefore, they are not expected to influence the results.

Another study limitation is the potential bias arising from eligible women who elected not to travel to their local health clinics for study enrollment. While reimbursement was provided for round-trip travel expenses to encourage and facilitate enrollment of women with limited resources or those who lived further from the clinics, this reimbursement was only provided upon arrival at the clinic. Women who lacked cash for the initial journey or who had limited access to transportation in the rural and dispersed study area may have been less likely to enroll in the study. Women engaged in work or schooling outside the home or who had heavy responsibilities at home or on the farm including care for children or other family members may also have been less likely to travel for enrollment. Some of these women, particularly poorer women and those living in more remote or marginal areas, may have been at higher risk of anemia and nutritional deficiencies, indicating the need for strategies for difficult-to-reach populations.

Given high fertility and the nutritional demands of repeated pregnancies and prolonged periods of lactation, interventions, programs, and services aimed at improving nutritional status among adolescents before they initiate childbearing may be particularly effective in improving maternal and child outcomes. Improvement in a girl’s stature prior to childbearing can have positive intergenerational consequences [38, 39], and reducing anemia in adolescent girls and non-pregnant women would also have benefits beyond those related to future pregnancy, including increased work capacity and productivity, cognitive development, and resistance to infection, all of which have economic implications [40, 41]. Correcting iron and other nutritional deficiencies can also have positive effects on mental health, related to or separate from pregnancy [42, 43]. However, reaching non-pregnant women and adolescent girls remains a challenge, and more work is needed on effective entry points such as schools before girls complete or discontinue their education; events surrounding key life stages such as marriage; or health system interventions or programs such as visits by community health workers or wellness visits at health facilities based on age [44].

While daily pre-pregnancy supplementation of women and adolescent girls may be efficacious in reducing the risk of anemia and other nutritional deficiencies, it poses significant challenges for sustainable delivery and compliance. Weekly supplementation can be an effective alternative [45, 46]. However, a meta-analysis of daily or intermittent iron supplementation to reduce the risk of iron deficiency anemia concluded that neither is likely to be effective unless programs or interventions have good supervision and good compliance, and weekly supplementation may be disadvantageous when the baseline anemia prevalence is high [47]. Interventions providing weekly iron and folic acid supplements to women of reproductive age in Vietnam, the Philippines, and Cambodia were successful in improving anemia and iron status using social marketing, community mobilization, and a government-industry partnership to promote the approach [11, 13, 14].

Other delivery methods, such as micronutrient powders administered daily or on a flexible schedule, may have greater acceptance and compliance and should be investigated [48]. Community mobilization and modes of delivery other than supplement pills can be important in areas, such as this study’s location, where stigma against antiretroviral therapy (ART) for HIV infection is prevalent [49] and family or community members could confuse regular use of supplement pills with ART usage. Participants in this study were highly mobile, and flexible administration could also be useful as young women and adolescent girls leave school, migrate to urban areas, engage in work outside the home, marry, divorce, or travel to visit relatives, give birth, or engage in agricultural or other seasonal or short-term labor.

Intermittent supplementation may also be an effective option to prevent anemia in populations with a high burden of infectious diseases. The safety of iron supplements for individuals with malaria, HIV, and hepatitis B and C has been debated as iron could worsen infection [5053]. However, these and other diseases, in particular malaria [54] and HIV [55], also cause anemia and are significant public health concerns in Tanzania. While iron supplementation did not increase the risk of malaria in this study, monitoring for potential harm is indicated especially in areas with high malaria prevelance, and intermittent supplementation may be an effective way to prevent anemia without providing excess iron to stimulate pathogens or parasites in endemic areas.


The authors would like to thank field supervisors Hamdan Kiliyamali and Twalib Mtupa, laboratory specialist Christopher Membi, research coordinator Anne Marie Darling, and the field enumerators, data clerks, and staff at the Ifakara Health Institute Rufiji Office for their efforts and commitment to this study. We also thank the administration and laboratory staff at the Mchukwi Mission Hospital, Kibiti Health Center, and Ikwiriri Health Center, including our late colleague Tausi Shabani. We are grateful for the women who participated in this study and their families for their time, interest, and support.

Author Contributions

Conceived and designed the experiments: HM WF. Performed the experiments: NG FL SM NS KI MS EE. Analyzed the data: NG FL DS EH. Wrote the paper: NG.


  1. 1. Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: Systematic review and meta-analysis. British Medical Journal. 2013;346:f3443. pmid:23794316
  2. 2. Stoltzfus RJ, Mullany L, Black RE. Chapter 3. Iron-deficiency anemia. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks: Global and regional burden of disease attributable to selected major risk factors. 1. Geneva: World Health Organization; 2004. p. 163–209.
  3. 3. Balarajan Y, Ramakrishnan U, Özaltin E, Shankar AH, Subramanian SV. Anaemia in low-income and middle-income countries. The Lancet. 2011;378:2123–35. pmid:21813172
  4. 4. Scholl TO. Maternal iron status: relation to fetal growth, length of gestation, and iron endowment of the neonate. Nutrition Reviews. 2011;69:S23–S9. pmid:22043878
  5. 5. Bothwell TH. Iron requirements in pregnancy and strategies to meet them. American Journal of Clinical Nutrition. 2000;72:257S–64S. pmid:10871591
  6. 6. Ramakrishnan U, Grant F, Goldenberg T, Zongrone A, Martorell R. Effect of women’s nutrition before and during early pregnancy on maternal and infant outcomes: A systematic review. Paediatric and Perinatal Epidemiology. 2012;26(S1):285–301. pmid:22742616
  7. 7. Cetin I, Berti C, Calabrese S. Role of micronutrients in the periconceptional period. Human Reproduction Update. 2010;16(1):80–95. pmid:19567449
  8. 8. De-Regil LM, Fernández-Gaxiola AC, Dowswell T, Peña-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database of Systematic Reviews. 2010;10:CD007950. pmid:20927767
  9. 9. Berry RJ, Bailey L, Mulinare J, Bower C, Dary O. Fortification of flour with folic acid. Food and Nutrition Bulletin. 2010;31:S22–S35. pmid:20629350
  10. 10. Ronnenberg AG, Wood RJ, Wang X, Xing H, Chen C, Chen D, et al. Preconception hemoglobin and ferritin concentrations are associated with pregnancy outcome in a prospective cohort of Chinese women. Journal of Nutrition. 2004;134:2586–91. pmid:15465752
  11. 11. Berger J, Thanh HTK, Cavalli-Sforza T, Smitasiri S, Khan NC, Milani S, et al. Community mobilization and social marketing to promote weekly iron-folic acid supplementation in women of reproductive age in Vietnam: Impact on anemia and iron status. Nutrition Reviews. 2005;63:S95–S108. pmid:16466085
  12. 12. Cavalli-Sforza T. Effectiveness of weekly iron-folic acid supplementation to prevent and control anemia among women of reproductive age in three asian countries: Development of the master protocol and implementation plan. Nutrition Reviews. 2005;63:S77–S80. pmid:16466082
  13. 13. Angeles-Agdeppa I, Paulino LS, Ramos AC, Etorma UM, Cavalli-Sforza T, Milani S. Government-industry partnership in weekly iron-folic acid supplementation for women of reproductive age in the Philippines: Impact on iron status. Nutrition Reviews. 2005;63:S116–S25. pmid:16466087
  14. 14. Crape BL, Kenefick E, Cavalli-Sforza T, Busch-Hallen J, Milani S, Kanal K. Positive impact of a weekly iron-folic acid supplement delivered with social marketing to Cambodian women: Compliance, participation, and hemoglobin levels increase with higher socioeconomic status. Nutrition Reviews. 2005;63:S134–S8. pmid:16466089
  15. 15. Mason J, Bailes A, Beda-Andourou M, Copeland N, Curtis T, Deitchler M, et al. Recent trends in malnutrition in developing regions: Vitamin A deficiency, anemia, iodine deficiency, and child underweight. Food and Nutrition Bulletin. 2005;26:59–162. pmid:15810801
  16. 16. de Benoist B, McLean E, Egli I, Cogswell M, editors. Worldwide prevalence of anaemia 1993–2005. Geneva: World Health Organization; 2008.
  17. 17. National Bureau of Statistics, ICF Macro. Tanzania Demographic and Health Survey 2010. Dar es Salaam, Tanzania: 2011.
  18. 18. Mpembeni RNM, Killewo JZ, Leshabari MT, Massawe SN, Jahn A, Mushi D, et al. Use pattern of maternal health services and determinants of skilled care during delivery in Southern Tanzania: Implications for achievement of MDG-5 targets. BMC Pregnancy and Childbirth. 2007;7:29. pmid:18053268
  19. 19. Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press; 1998.
  20. 20. Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington DC: National Academy Press; 2000.
  21. 21. Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington DC: National Academy Press; 2001.
  22. 22. Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT. Williams Hematology, Eighth Edition. New York: McGraw-Hill Medical; 2010.
  23. 23. WHO. Iron deficiency anaemia: Assessment, prevention and control. A guide for programme managers. Geneva: 2001 Contract No.: WHO/NHD/01.3.
  24. 24. Agresti A. An Introduction to Categorical Data Analysis, Second Edition. New York: John Wiley and Sons; 2007.
  25. 25. Robins JM, Hernán MÁ, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550–60. pmid:10955408
  26. 26. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. American Journal of Epidemiology. 2005;162(3):199–200. pmid:15987728
  27. 27. Lolascon A, De Falco L, Beaumont C. Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis. Haematologica. 2009;94:395–408. pmid:19181781
  28. 28. Allen LH. Biological mechanisms that might underlie iron’s effects on fetal growth and preterm birth. Journal of Nutrition. 2001;131:581S–9S. pmid:11160591
  29. 29. Gambling L, Charania Z, Hannah L, Antipatis C, Lea RG, McArdle HJ. Effect of iron deficiency on placental cytokine expression and fetal growth in the pregnant rat. Biology of Reproduction. 2002;66:516–23. pmid:11804970
  30. 30. Hindmarsh PC, Geary MPP, Rodeck CH, Jackson MR, Kingdom JCP. Effect of early maternal iron stores on placental weight and structure. The Lancet. 2000;356:719–23. pmid:11085691
  31. 31. Khambalia A, O’Connor DL, Zlotkin S. Periconceptional iron and folate status is inadequate among married, nulliparous women in rural Bangladesh. Journal of Nutrition. 2009;139:1179–84. pmid:19403710
  32. 32. Zhang Q, Li Z, Ananth CV. Prevalence and risk factors for anaemia in pregnant women: A population-based prospective cohort study in China. Paediatric and Perinatal Epidemiology. 2009;23(4):282–91. pmid:19523075
  33. 33. Corwin EJ, Murray-Kolb LE, Beard JL. Low hemoglobin level is a risk factor for postpartum depression. Journal of Nutrition. 2003;133:4139–42. pmid:14652362
  34. 34. Ogundipe O, Hoyo C, Østbye T, Oneko O, Manongi R, Lie RT, et al. Factors associated with prenatal folic acid and iron supplementation among 21,889 pregnant women in Northern Tanzania: A cross-sectional hospital-based study. BMC Public Health. 2012;12:481. pmid:22734580
  35. 35. Casey GJ, Jolley D, Phuc TQ, Tinh TT, Tho DH, Montresor A, et al. Long-Term Weekly Iron-Folic Acid and De-Worming Is Associated with Stabilised Haemoglobin and Increasing Iron Stores in Non-Pregnant Women in Vietnam. PLoS ONE. 2010;5(12):e15691. pmid:21209902
  36. 36. Fernández-Gaxiola AC, De-Regil LM. Intermittent iron supplementation for reducing anaemia and its associated impairments in menstruating women. Cochrane Database of Systematic Reviews. 2011;12:CD009218. pmid:22161448
  37. 37. Bain BJ. Haemoglobinopathy Diagnosis, 2nd Edition. Malden, MA, USA: Blackwell; 2006.
  38. 38. Prentice AM, Ward KA, Goldberg GR, Jarjou LM, Moore SE, Fulford AJ, et al. Critical windows for nutritional interventions against stunting. American Journal of Clinical Nutrition. 2013;97:911–8. pmid:23553163
  39. 39. Martorell R, Zongrone A. Intergenerational influences on child growth and undernutrition. Paediatric and Perinatal Epidemiology. 2012;26:302–14. pmid:22742617
  40. 40. Haas JD, Brownlie IV T. Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship. Journal of Nutrition. 2001;131:676S–90S. pmid:11160598
  41. 41. Horton S, Ross J. The economics of iron deficiency. Food Policy. 2003;28:51–75.
  42. 42. Patterson AJ, Brown WJ, Roberts DCK. Dietary and supplement treatment of iron deficiency results in improvements in general health and fatigue in Australian women of childbearing age. Journal of the American College of Nutrition. 2001;20:337–42. pmid:11506061
  43. 43. Bodnar LM, Wisner KL. Nutrition and depression: Implications for improving mental health among childbearing-aged women. Biological Psychiatry. 2005;58:679–85. pmid:16040007
  44. 44. Temin M, Levine R. Start with a girl: A new agenda for global health. Washington, D.C.: Center for Global Development, 2009.
  45. 45. Viteri FE, Berger J. Importance of pre-pregnancy and pregnancy iron status: can long-term weekly preventive iron and folic acid supplementation achieve desirable and safe status? Nutrition Reviews. 2005;63:S65–S76. pmid:16466081
  46. 46. Casey GJ, Montresor A, Cavalli-Sforza LT, Thu H, Phu LB, Tinh TT, et al. Elimination of Iron Deficiency Anemia and Soil Transmitted Helminth Infection: Evidence from a Fifty-four Month Iron-Folic Acid and De-worming Program. PLoS Negl Trop Dis. 2013;7(4):e2146. pmid:23593517
  47. 47. Beaton GH, McCabe GP. Efficacy of intermittent iron supplementation in the control of iron deficiency anaemia in developing countries: An analysis of experience. Report to the Micronutrient Initiative and the Canadian International Development Agency, 1999.
  48. 48. Ip H, Hyder SM, Haseen F, Rahman M, Zlotkin SH. Improved adherence and anaemia cure rates with flexible administration of micronutrient Sprinkles: A new public health approach to anaemia control. European Journal of Clinical Nutrition. 2009;63:165–72. pmid:17895911
  49. 49. Agnarson AM, Masanja H, Ekström AM, Eriksen J, Tomson G, Thorson A. Challenges to ART scale-up in a rural district in Tanzania: Stigma and distrust among Tanzanian health care workers, people living with HIV and community members. Tropical Medicine and International Health. 2010;15(9):1000–7. pmid:20636305
  50. 50. Weinberg ED. Iron loading and disease surveillance. Emerging Infectious Diseases. 1999;5(3):346–52. pmid:10341171
  51. 51. Khan FA, Fisher MA, Khakoo RA. Association of hemochromatosis with infectious diseases: expanding spectrum. International Journal of Infectious Diseases. 2007;11(6):482–7. pmid:17600748
  52. 52. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. The Lancet. 2006;367(9505):133–43. pmid:16413877
  53. 53. Iron and Malaria Technical Working Group. Considerations for the safe and effective use of iron interventions in areas of malaria burden: Full technical report. National Institutes of Health (NIH), 2009.
  54. 54. Menendez C, Fleming AF, Alonso PL. Malaria-related anaemia. Parasitology Today. 2000;16:469–76. pmid:11063857
  55. 55. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, et al. Anemia in HIV infection: Clinical impact and evidence-based management strategies. Clinical Infectious Diseases. 2004;38:1454–63. pmid:15156485